Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
33.51
+0.05 (0.15%)
At close: May 30, 2025, 4:00 PM
33.06
-0.45 (-1.34%)
After-hours: May 30, 2025, 4:08 PM EDT
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 17 professional analysts, the 12-month price target for Ionis Pharmaceuticals stock ranges from a low of $37 to a high of $77. The average analyst price target of $57.41 forecasts a 71.32% increase in the stock price over the next year.
Price Target: $57.41 (+71.32%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 7 | 7 |
| Buy | 7 | 7 | 7 | 6 | 4 | 4 |
| Hold | 5 | 5 | 5 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 18 | 18 | 19 | 19 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +49.21% | May 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $65 → $64 | Strong Buy | Maintains | $65 → $64 | +90.99% | May 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $50 | Strong Buy | Maintains | $45 → $50 | +49.21% | May 1, 2025 |
| Needham | Needham | Strong Buy Maintains $60 → $55 | Strong Buy | Maintains | $60 → $55 | +64.13% | Apr 30, 2025 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +79.05% | Apr 15, 2025 |
Financial Forecast
Revenue This Year
755.50M
from 705.14M
Increased by 7.14%
Revenue Next Year
898.18M
from 755.50M
Increased by 18.89%
EPS This Year
-3.24
from -3.04
EPS Next Year
-3.08
from -3.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 841.1M | 1.4B | 1.6B | ||
| Avg | 755.5M | 898.2M | 1.2B | ||
| Low | 653.0M | 708.1M | 395.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.3% | 79.9% | 80.7% | ||
| Avg | 7.1% | 18.9% | 34.4% | ||
| Low | -7.4% | -6.3% | -55.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.43 | -1.47 | -0.41 | ||
| Avg | -3.24 | -3.08 | -1.53 | ||
| Low | -4.13 | -4.18 | -3.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.